WOCKPHARMA2024-04-012024-06-30 WOCKPHARMA2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2024-06-30 WOCKPHARMA2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2024-04-01 2025-03-31 2024-08-09 2024-08-05 INR Crores First quarter 12:20:00 14:50:00 2024-08-09 2024-08-09 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 7390000000.00 300000000.00 7690000000.00 1500000000.00 1530000000.00 100000000.00 1600000000.00 730000000.00 540000000.00 1750000000.00 7750000000.00 -60000000.00 0.00 -60000000.00 20000000.00 80000000.00 100000000.00 0.00 -160000000.00 0.00 0.00 0.00 0.00 -160000000.00 -30000000.00 -190000000.00 -140000000.00 -20000000.00 -180000000.00 -10000000.00 770000000.00 5 -0.95 -0.95 0.00 0.00 -0.95 -0.95 0.00 0.00 0.00 Notes To Consolidated Results:- 1.The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 09, 2024. The results have been subjected to Limited review by the Statutory Auditors of the Company. 2.The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 3.Key Financials on Standalone basis: 3 Months Ended Year Ended Particulars 30/06/24 31/03/24 30/06/23 31/03/24 Unaudited Audited Unaudited Audited Total Income 379 379 257 1,195 Profit(Loss)before tax 6 (126) (115) (422) Profit(Loss) after tax 6 (126) (115) (422) Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 4.Figures for the quarter ended March 31, 2024 is the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2023-24. 5.The Group is exclusively into Pharmaceutical business Segment. 6.For List of Subsidiaries as on June 30, 2024 please refer Annexure to note 6 of consolidated unaudited results for the quarter ended June 30, 2024. Exchange Fluctuation loss,net 10000000.00 Other expenses 1740000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) (Continuing operations) 0.00 0.00 0.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) -30000000.00 -30000000.00 0.00